Teclistamab Access Program for Patients with Difficult-to-Treat Multiple Myeloma

Sponsor: Janssen Research & Development, LLC

Expanded Access
Approved for Marketing
Sponsor score: 60
Inactive

ClinicalTrials ID:NCT05463939

Provider View

This program allows patients with relapsed or refractory multiple myeloma, who have no other treatment options, to access teclistamab before it is officially approved for the market.

Patient Parameters

Program Overview

The goal of this program is to provide access to the drug teclistamab for patients with multiple myeloma that has returned or not responded to treatment, and who have no other available treatment options. This is for patients who cannot join a clinical trial for teclistamab.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with relapsed or refractory multiple myeloma.
  • Have tried all available and suitable treatments, and cannot join a clinical trial for teclistamab.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.